JPMorgan Chase & Co. Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price

Revvity (NYSE:RVTY) had its price objective lowered by stock analysts at JPMorgan Chase & Co. from $96.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential downside of 9.55% from the company’s current price.

RVTY has been the topic of a number of other reports. Evercore boosted their target price on shares of Revvity from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Barclays reiterated an “equal weight” rating and issued a $95.00 target price (down from $118.00) on shares of Revvity in a research note on Tuesday, April 14th. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. TD Cowen boosted their target price on shares of Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Stifel Nicolaus dropped their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $106.82.

Revvity Stock Up 7.8%

Revvity stock traded up $7.20 during midday trading on Wednesday, hitting $99.50. 3,014,194 shares of the stock were exchanged, compared to its average volume of 1,293,190. Revvity has a 52-week low of $81.22 and a 52-week high of $118.30. The stock has a market capitalization of $11.12 billion, a price-to-earnings ratio of 47.84, a price-to-earnings-growth ratio of 1.84 and a beta of 1.05. The business’s 50-day moving average price is $90.23 and its 200-day moving average price is $96.82. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the previous year, the company earned $1.01 earnings per share. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, research analysts expect that Revvity will post 5.39 EPS for the current fiscal year.

Institutional Trading of Revvity

Institutional investors have recently modified their holdings of the business. Ascentis Independent Advisors purchased a new stake in shares of Revvity during the 1st quarter valued at approximately $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity during the 2nd quarter valued at approximately $32,000. Cromwell Holdings LLC lifted its stake in shares of Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares in the last quarter. MUFG Securities EMEA plc bought a new stake in Revvity during the 2nd quarter worth approximately $34,000. Finally, Headlands Technologies LLC bought a new stake in Revvity during the 2nd quarter worth approximately $49,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 beat — Revvity reported EPS of $1.06 versus consensus $1.02 and revenue of $711.1M vs. $704.1M, showing 7% y/y revenue growth; the beat is the main near-term bullish trigger. Article Title
• Positive Sentiment: Analyst uplift — TD Cowen raised its price target to $120 and kept a Buy rating, signaling further upside potential and likely supporting fresh buying interest. Article Title
• Neutral Sentiment: Underlying performance — company cited ~3% organic growth and portfolio execution that helped offset margin pressure; this context explains the beat but is not unambiguously directional. Article Title
• Neutral Sentiment: Full disclosure available — earnings transcript and slide deck were published (useful for investors to check management commentary on margins, China ImmunoDx plans and product/product-line trends). Article Title
• Negative Sentiment: Guidance trimmed — Revvity set FY26 EPS guidance of $5.20–$5.30 (below Wall Street’s ~$5.40) and issued revenue guidance around $2.8B vs. ~ $3.0B consensus, which introduces longer‑term growth/visibility concerns and can limit multiple expansion. Article Title
• Negative Sentiment: Mixed analyst tone — Robert W. Baird cut its price target (to $125) and the broker consensus average sits around “Hold,” indicating some analysts are cautious despite the beat. Article Title

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.